160 related articles for article (PubMed ID: 16786512)
21. The role of SH3BP2 in the pathophysiology of cherubism.
Reichenberger EJ; Levine MA; Olsen BR; Papadaki ME; Lietman SA
Orphanet J Rare Dis; 2012 May; 7 Suppl 1(Suppl 1):S5. PubMed ID: 22640988
[TBL] [Abstract][Full Text] [Related]
22. A c.1244G>A (p.Arg415Gln) mutation in SH3BP2 gene causes cherubism in a Turkish family: report of a family with review of the literature.
Sekerci AE; Balta B; Dundar M; Hu Y; Reichenberger EJ; Etoz OA; Nazlim S; Bayrakdar IS
Med Oral Patol Oral Cir Bucal; 2014 Jul; 19(4):e340-4. PubMed ID: 24608212
[TBL] [Abstract][Full Text] [Related]
23. [Molecular and Cellular Pathogenesis of Cherubism].
Ueki Y
Clin Calcium; 2016 Jun; 26(6):918-26. PubMed ID: 27230848
[TBL] [Abstract][Full Text] [Related]
24. Characterization of a Norwegian cherubism cohort; molecular genetic findings, oral manifestations and quality of life.
Prescott T; Redfors M; Rustad CF; Eiklid KL; Geirdal AØ; Storhaug K; Jensen JL
Eur J Med Genet; 2013 Mar; 56(3):131-7. PubMed ID: 23298620
[TBL] [Abstract][Full Text] [Related]
25. SH3BP2 is an activator of NFAT activity and osteoclastogenesis.
Lietman SA; Yin L; Levine MA
Biochem Biophys Res Commun; 2008 Jul; 371(4):644-8. PubMed ID: 18440306
[TBL] [Abstract][Full Text] [Related]
26. Cherubism allele heterozygosity amplifies microbe-induced inflammatory responses in murine macrophages.
Prod'Homme V; Boyer L; Dubois N; Mallavialle A; Munro P; Mouska X; Coste I; Rottapel R; Tartare-Deckert S; Deckert M
J Clin Invest; 2015 Apr; 125(4):1396-400. PubMed ID: 25705883
[TBL] [Abstract][Full Text] [Related]
27. DNA analysis of the SH3BP2 gene in patients with aggressive central giant cell granuloma.
de Lange J; van Maarle MC; van den Akker HP; Redeker EJ
Br J Oral Maxillofac Surg; 2007 Sep; 45(6):499-500. PubMed ID: 16713042
[TBL] [Abstract][Full Text] [Related]
28. Jawing about TNF: new hope for cherubism.
Novack DV; Faccio R
Cell; 2007 Jan; 128(1):15-7. PubMed ID: 17218248
[TBL] [Abstract][Full Text] [Related]
29. Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 "cherubism" mice.
Ueki Y; Lin CY; Senoo M; Ebihara T; Agata N; Onji M; Saheki Y; Kawai T; Mukherjee PM; Reichenberger E; Olsen BR
Cell; 2007 Jan; 128(1):71-83. PubMed ID: 17218256
[TBL] [Abstract][Full Text] [Related]
30. Pro416Arg cherubism mutation in Sh3bp2 knock-in mice affects osteoblasts and alters bone mineral and matrix properties.
Wang CJ; Chen IP; Koczon-Jaremko B; Boskey AL; Ueki Y; Kuhn L; Reichenberger EJ
Bone; 2010 May; 46(5):1306-15. PubMed ID: 20117257
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathologic and Molecular Characteristics of Familial Cherubism with Associated Odontogenic Tumorous Proliferations.
Argyris PP; Gopalakrishnan R; Hu Y; Reichenberger EJ; Koutlas IG
Head Neck Pathol; 2018 Mar; 12(1):136-144. PubMed ID: 28721660
[TBL] [Abstract][Full Text] [Related]
32. Cherubism gene Sh3bp2 is important for optimal bone formation, osteoblast differentiation, and function.
Mukherjee PM; Wang CJ; Chen IP; Jafarov T; Olsen BR; Ueki Y; Reichenberger EJ
Am J Orthod Dentofacial Orthop; 2010 Aug; 138(2):140.e1-140.e11; discussion 140-1. PubMed ID: 20691350
[TBL] [Abstract][Full Text] [Related]
33. Molecular and cellular characterizations of human cherubism: disease aggressiveness depends on osteoclast differentiation.
Kadlub N; Sessiecq Q; Mandavit M; L'Hermine AC; Badoual C; Galmiche L; Berdal A; Descroix V; Picard A; Coudert AE
Orphanet J Rare Dis; 2018 Sep; 13(1):166. PubMed ID: 30236129
[TBL] [Abstract][Full Text] [Related]
34. A missense mutation in the SH3BP2 gene on chromosome 4p16.3 found in a case of nonfamilial cherubism.
Imai Y; Kanno K; Moriya T; Kayano S; Seino H; Matsubara Y; Yamada A
Cleft Palate Craniofac J; 2003 Nov; 40(6):632-8. PubMed ID: 14577811
[TBL] [Abstract][Full Text] [Related]
35. [SH3BP2 heterozygous mutation amplifies macrophage inflammatory responses to infection in a mouse model of cherubism].
Deckert M; Prod'Homme V
Med Sci (Paris); 2015; 31(6-7):589-91. PubMed ID: 26152156
[No Abstract] [Full Text] [Related]
36. Familial cherubism: clinical and radiological features. Case report and review of the literature.
Sidorowicz W; Kubasiewicz-Ross P; Dominiak M
Eur J Paediatr Dent; 2018 Sep; 19(3):213-217. PubMed ID: 30063153
[TBL] [Abstract][Full Text] [Related]
37. Etanercept administration to neonatal SH3BP2 knock-in cherubism mice prevents TNF-α-induced inflammation and bone loss.
Yoshitaka T; Ishida S; Mukai T; Kittaka M; Reichenberger EJ; Ueki Y
J Bone Miner Res; 2014; 29(5):1170-82. PubMed ID: 24978678
[TBL] [Abstract][Full Text] [Related]
38. Cherubism as a systemic skeletal disease: evidence from an aggressive case.
Morice A; Joly A; Ricquebourg M; Maruani G; Durand E; Galmiche L; Amiel J; Vial Y; Cavé H; Belhous K; Piketty M; Cohen-Solal M; Berdal A; Collet C; Picard A; Coudert AE; Kadlub N
BMC Musculoskelet Disord; 2020 Aug; 21(1):564. PubMed ID: 32825821
[TBL] [Abstract][Full Text] [Related]
39. Anti-tumor necrosis factor treatment in cherubism--clinical, radiological and histological findings in two children.
Hero M; Suomalainen A; Hagström J; Stoor P; Kontio R; Alapulli H; Arte S; Toiviainen-Salo S; Lahdenne P; Mäkitie O
Bone; 2013 Jan; 52(1):347-53. PubMed ID: 23069372
[TBL] [Abstract][Full Text] [Related]
40. The calcineurin inhibitor tacrolimus as a new therapy in severe cherubism.
Kadlub N; Vazquez MP; Galmiche L; L'Herminé AC; Dainese L; Ulinski T; Fauroux B; Pavlov I; Badoual C; Marlin S; Deckert M; Leboulanger N; Berdal A; Descroix V; Picard A; Coudert AE
J Bone Miner Res; 2015 May; 30(5):878-85. PubMed ID: 25491283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
